[HTML][HTML] Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients

HJ Kolb, J Mittermüller, CH Clemm, E Holler… - Blood, 1990 - Elsevier
HJ Kolb, J Mittermüller, CH Clemm, E Holler, G Ledderose, G Brehm, M Heim, W Wilmanns
Blood, 1990Elsevier
Three patients with hematologic relapse after bone marrow transplantation for chronic
myelogenous leukemia were treated with interferon α and transfusion of viable donor buffy
coat. All had complete hematologic and cytogenetic remission, which persisted 32 to 91
weeks after treatment. In two patients graft-versus-host disease developed and was treated
by immunosuppression. These results are an example of adoptive immunotherapy without
cytoreductive chemotherapy or radiotherapy in human chimeras.
Abstract
Three patients with hematologic relapse after bone marrow transplantation for chronic myelogenous leukemia were treated with interferon α and transfusion of viable donor buffy coat. All had complete hematologic and cytogenetic remission, which persisted 32 to 91 weeks after treatment. In two patients graft-versus-host disease developed and was treated by immunosuppression. These results are an example of adoptive immunotherapy without cytoreductive chemotherapy or radiotherapy in human chimeras.
Elsevier